Plain-English translation of NCT06932003 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing an experimental oral tablet called LT-002-158 to see if it can help treat moderate-to-severe hidradenitis suppurativa (HS)—a painful chronic skin condition marked by recurring abscesses and inflamed bumps. The trial will first check whether the medication is safe and well-tolerated, then test whether it actually works to reduce symptoms. If you enroll, you may receive the medication or a placebo (inactive pill), depending on which part of the study you're in.
Current treatments for severe HS don't work well enough for all patients, or some people can't tolerate them. This trial aims to find out whether this new medication could offer a better option for people whose HS hasn't improved with existing therapies.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. First, all participants will take the medication to see if it is safe and causes side effects. Then, in the second phase, participants will be randomly assigned to either take the medication or a placebo for a set period, with visits to the clinic for check-ups and blood tests. You'll also keep a daily diary to track your skin condition. The study takes place at a clinic in China and involves multiple visits over several months to monitor how well the treatment works and whether you experience any problems.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
China